SEC Form 4
BioNTech SE (BNTX) insider trading
In the 12 months to Oct 26, 2026, 2 BNTX insiders reported open-market sales of $89.8M across 15 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $89.8M
- 15 filings · 2 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 15 of 15
- All $89.8M sold was pre-arranged
Who traded BNTX, and when
- Sale
- Sale, pre-arranged (10b5-1)
BNTX daily close from Oct 27, 2025 to Oct 26, 2026, between $83.89 and $119.34, last $87.14. 15 sale and 0 purchase filings by 2 insiders, marked at their filing dates. Ugur Sahin, Chief Executive Officer: sold $84.2M across 14 filings, first filed Sep 8, 2026, last Oct 9, 2026. Sierk Poetting, Chief Operating Officer: sold $5.5M across 1 filing, first filed Apr 23, 2026, last Apr 23, 2026.
Largest mark · tap a row for others
Ugur Sahin · Chief Executive Officer
Filing 1 of 4 within a week · $25,493,342 total
Sale $7,889,055
76,500 shares
Filed Sep 8, 2026 · traded Sep 3
Pre-arranged (10b5-1) · close on filing date $98.66
Ugur Sahin · Chief Executive Officer
Chief Executive Officer
$84.2M soldSierk Poetting · Chief Operating Officer
Chief Operating Officer
$5.5M soldOpen-market trades
15 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Ugur Sahin | Chief Executive Officer | $84.2M | — | 14 | 100% of sales | |
| Sierk Poetting | Chief Operating Officer | $5.5M | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Value | Held after | Source |
|---|---|---|---|---|---|---|
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 63,209 ordinary shares | $5.9M | 0 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 24,000 ordinary shares | $2.3M | 63,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 93,000 ordinary shares | $9.0M | 87,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 34,000 ordinary shares | $3.3M | 180,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 66,000 ordinary shares | $6.5M | 214,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 61,000 ordinary shares | $6.0M | 280,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 69,000 ordinary shares | $6.8M | 341,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 79,000 ordinary shares | $7.9M | 410,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 64,000 ordinary shares | $6.2M | 489,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 49,000 ordinary shares | $4.7M | 553,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 86,000 ordinary shares | $8.4M | 602,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 20,500 ordinary shares | $2.0M | 688,209 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 73,000 ordinary shares | $7.2M | 708,709 | |
traded | Ugur Sahin Chief Executive Officer | SalePre-arranged (10b5-1) | 76,500 ordinary shares | $7.9M | 781,709 | |
traded | Sierk Poetting Chief Operating Officer | SalePre-arranged (10b5-1) | 50,000 ordinary shares | $5.5M | 399,387 |
Shares are as filed (ordinary shares or ADS); values are as converted to US$ in the filing.
GET /stocks/filings/vX/form-4?tickers=BNTX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BNTX"
],
"issuer_cik": "0001776985",
"owner_cik": "0002123975",
"accession_number": "0002123975-26-000035",
"form_type": "4",
"filing_date": "2026-10-09",
"period_of_report": "2026-10-08",
"issuer_name": "BioNTech SE",
"issuer_trading_symbol": "BNTX",
"owner_name": "Sahin Ugur",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": true,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-09",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 36209,
"transaction_price_per_share": 95.3733,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 0,
"transaction_value": 3453371.8197,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"remarks": "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026."
},
{
"tickers": [
"BNTX"
],
"issuer_cik": "0001776985",
"owner_cik": "0002123975",
"accession_number": "0002123975-26-000035",
"form_type": "4",
"filing_date": "2026-10-09",
"period_of_report": "2026-10-08",
"issuer_name": "BioNTech SE",
"issuer_trading_symbol": "BNTX",
"owner_name": "Sahin Ugur",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": true,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-08",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 27000,
"transaction_price_per_share": 92.3142,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 36209,
"transaction_value": 2492483.4,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"remarks": "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has BioNTech SE's CEO sold stock?
Yes. Ugur Sahin (CEO) sold 858,209 shares ($84.2M) between Sep 2026 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is BNTX’s insider data?
These are BNTX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track BNTX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BNTX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.